ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

ClinicalTrials.gov ID: NCT07284433

Public ClinicalTrials.gov record NCT07284433. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 11:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-arm, Multicenter, Open-label, Phase I/II Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies

Study identification

NCT ID
NCT07284433
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
AvenCell Therapeutics, Inc.
Industry
Enrollment
178 participants

Conditions and interventions

Interventions

  • Allo-QuadCAR01-T Drug
  • Cyclophosphamide (Non-IMP, Lymphodepletion) Other
  • Fludarabine (Non-IMP, Lymphodepletion) Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 5, 2026
Primary completion
Apr 26, 2029
Completion
Nov 1, 2029
Last update posted
Apr 1, 2026

2026 – 2029

United States locations

U.S. sites
5
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
University of Chicago Chicago Illinois 60637 Not yet recruiting
Northwestern University Evanston Illinois 60208 Not yet recruiting
Brown University Health Providence Rhode Island 02903 Not yet recruiting
Sarah Cannon Research Institute Nashville Tennessee 37203 Recruiting
MD Anderson Cancer Center Houston Texas 77030 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07284433, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07284433 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →